HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: 292/1/G419    most recent 00289.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Wang, L. Articles by Taché, Y. Search for Related Content PubMed PubMed Citation Articles by Wang, L. Articles by Taché, Y.

REPORTS

5-Hydroxytryptophan activates colonic myenteric neurons and propulsive motor function through 5-HT₄ receptors in conscious mice

¹Center for Ulcer Research and Education: Digestive Diseases Research Center and Center for Neurovisceral Sciences and Woman's Health, Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, and ²Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; ³Molecular Neuroscience Research Center, Shiga University Medical Science, Otsu, Japan

Submitted 30 June 2006 ; accepted in final form 16 September 2006

ABSTRACT

Serotonin [5-hydroxytryptamine (5-HT)] acts as a modulator of colonic motility and secretion. We characterized the action of the 5-HT precursor 5-hydroxytryptophan (5-HTP) on colonic myenteric neurons and propulsive motor activity in conscious mice. Fos immunoreactivity (IR), used as a marker of neuronal activation, was monitored in longitudinal muscle/myenteric plexus whole mount preparations of the distal colon 90 min after an intraperitoneal injection of 5-HTP. Double staining of Fos IR with peripheral choline acetyltransferase (pChAT) IR or NADPH-diaphorase activity was performed. The injection of 5-HTP (0.5, 1, 5, or 10 mg/kg ip) increased fecal pellet output and fluid content in a dose-related manner, with a peak response observed within the first 15 min postinjection. 5-HTP (0.5–10 mg/kg) dose dependently increased Fos expression in myenteric neurons, with a maximal response of 9.9 ± 1.0 cells/ganglion [P < 0.05 vs. vehicle-treated mice (2.3 ± 0.6 cells/ganglion)]. There was a positive correlation between Fos expression and fecal output. Of Fos-positive ganglionic cells, 40 ± 4% were also pChAT positive and 21 ± 5% were NADPH-diaphorase positive in response to 5-HTP, respectively. 5-HTP-induced defecation and Fos expression were completely prevented by pretreatment with the selective 5-HT₄ antagonist RS-39604. These results show that 5-HTP injected peripherally increases Fos expression in different populations of cholinergic and nitrergic myenteric neurons in the distal colon and stimulates propulsive colonic motor function through 5-HT₄ receptors in conscious mice. These findings suggest an important role of activation of colonic myenteric neurons in the 5-HT₄ receptor-mediated colonic propulsive motor response.

cholinergic neurons; NADPH-diaphorase; peripheral choline acetyltransferase; serotonin; serotonin receptors

5-HT has also been implicated in the pathophysiology of several intestinal disorders, including functional bowel disorders such as irritable bowel syndrome (IBS) (3, 19, 34). In postinfectious or diarrhea-predominant IBS patients, reports have indicated the existence of significant cellular and molecular alterations of gut serotonergic signaling mechanisms, including an increase in the number of rectal EC cells, enhanced postprandial release of 5-HT, and altered expression of the 5-HT transporter (3, 8, 10, 13, 14, 34). Similar changes in the gut serotonergic system, resulting in the increased availability of 5-HT, have also been described in a mouse model of postinfectious IBS (63).

The colonic motor and secretory changes associated with increased levels of gut 5-HT are largely mediated through 5-HT₄ (19, 59) as well as 5-HT₃ receptors (27, 47). In rodents, 5-HT₄ receptors mediate colonic propulsive motor activity and defecation in response to exogenous or endogenous 5-HT, as shown by the use of peripheral injection of selective 5-HT₄ agonists and antagonists under in vivo and in vitro conditions (2, 22, 29, 41, 54, 56, 58). Clinical observations have also demonstrated that selective 5-HT₄ receptor agonists accelerate colonic transit in healthy subjects (1, 6) and in patients with the constipation-predominant form of IBS (11, 19). On the other hand, 5-HT₃ antagonists have been reported to have antidiarrheic effects in diarrhea-predominant IBS patients (20, 25). However, 5-HT₃ antagonists failed to influence human in vivo colonic or in vitro jejunal peristalsis (5, 15). In rodents, 5-HT₃ antagonists blocked 5-hydroxytryptophan (5-HTP)- or stress-induced stimulation of defecation (40, 47), and, in guinea pigs, recruitment of both 5-HT₃ and 5-HT₄ receptors may be needed to fully elicit 5-HT-induced stimulation of colonic motor function (27, 28). The prokinetic effect of 5-HT₃ receptors is mediated by afferent signaling from the gut to the brain via extrinsic afferent nerves and submucosal sensory neurons (19, 39). Supporting evidence is that 5-HT₃ receptors are localized on intrinsic sensory neurons and extrinsic sensory nerve fibers that innervate the rat colon (35), whereas 5-HT₄ receptors exist in interneurons and motor and sensory neurons as well as in smooth muscle cells in the intestine of rodents, guinea pigs, and humans (26, 32, 48, 51). Therefore, 5-HT₄ receptors are likely to be primarily involved in local mechanisms mediating the motor and secretory effects of 5-HT at a peripheral level.

Convergent data have established that the direct activation of 5-HT₄ receptors on colonic smooth muscle is inhibitory. Selective 5-HT₄ agonists induce a TTX-independent relaxation of the isolated human circular smooth muscle that is blocked by selective 5-HT₄ antagonists (49, 54, 59). By contrast, the neuronal action of 5-HT₄ receptor agonists is excitatory and exerted mainly by facilitating fast excitatory synaptic transmission, as shown by electrophysiological monitoring of myenteric neuron activity (31, 32). However, these prior studies on 5-HT₄-mediated myenteric actions have been all carried out in vitro using mainly guinea pig ileum longitudinal muscle/myenteric plexus (LMMP) preparations (31, 46), with the exception of one recent study (32) performed in cultured colonic myenteric neurons of young mice. We previously used Fos as a marker of neuronal activation (12) to establish that peripheral injection of corticotropin-releasing factor (CRF) induces a CRF₁ receptor-mediated activation of colonic myenteric neurons and propulsive motor function in conscious rats (36). This approach allowed us to monitor changes in the activity of myenteric neurons in conscious animals coupled with the simultaneous monitoring of functional changes of propulsive colonic activity leading to defecation.

The aim of the present study was to examine the colonic myenteric and propulsive responses induced by peripheral injection of the 5-HT precursor 5-HTP in conscious mice. 5-HTP was chosen to mimic a state of endogenous 5-HT production and release (55) at intestinal sites that normally synthesize 5-HT (64). 5-HTP-induced neuronal myenteric activation was assessed using Fos immunohistochemistry. The neurochemical phenotype of 5-HTP-activated neurons was examined using double labeling with Fos and peripheral choline acetyltransferase (pChAT), a marker of peripheral cholinergic neurons (43), or with NADPH-diaphorase, a cofactor of nitric oxide (NO) synthase (24). 5-HT₄ receptor-mediated actions of 5-HTP were assessed using the potent and selective 5-HT₄ antagonist RS-39604 (23). Finally, the magnitude of 5-HTP-induced defecation was compared with that of intraperitoneal injection of CRF-induced myenteric-mediated stimulation of colonic motor function in rodents (33, 36).

MATERIALS AND METHODS

Animals

Adult male C57BL/6 mice (6–8 wk of age; Harlan, San Diego, CA) were maintained on a 12:12-h light-dark cycle with controlled temperature (21–23°C) and humidity (30–35%). Animals were group housed in direct bedding cages with free access to food (Prolab RMH 2500, PMI Nutrition, Brentwood, MO) and tap water. Animals were moved to the experimental room 18–20 h before the experiments and housed individually, with water and food ad libitum. All the experiments were performed between 8:00 and 11:00 AM. To reduce the number of animals, when functional experiments were performed on colonic motor function, the same animal was used three times with at least a 5-day interval between consecutive experiments with treatments randomly assigned to the animals. Immunohistochemical experiments were conducted in naïve mice. All protocols were approved by the Veterans Affairs Animal Component of the Research Protocol (No. 99-092-05, Veterans Affairs Greater Los Angeles Healthcare System).

Compounds

L-2-Amino-3-(5-hydroxyindolyl)propionic acid (5-HTP; Sigma Chemical, St. Louis, MO) and rat/human CRF (r/hCRF; Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, CA) were dissolved in sterile saline. 1-[4-Amino-5-chloro-2-(3,5-dimethoxyphenyl)methyloxy]-3-{[1-(2-methylsulphonylamino)ethyl]piperidin-4-yl}propan-1-one hydrochloride (RS-39604, hydrochloride form; Tocris, Ellisville, MO) (23) was dissolved in 5% DMSO (Sigma)-5% Tween 80 (Sigma)-90% saline. Either sterile saline or 5% DMSO-5% Tween 80–90% saline, as appropriate, served as the vehicle control. All solutions were prepared immediately before use.

Defecation Score and Fecal Fluid Content

The numbers of fecal pellets excreted were determined at 15-min intervals for the 90-min period after treatments, and cumulative pellet output was calculated at the end of the experimental time. At every 15-min interval, all fecal pellets excreted were collected, weighed (wet weight, in mg), desiccated in an oven (50°C, 6 h), and weighed again (dry weight, in mg). The fecal fluid content percentage was calculated according to the following equation: fluid content (in %) = 100 x (wet weight – dry weight) ÷ wet weight.

Tissue Preparation of the Distal Colonic LMMP

Mice were euthanized by cervical dislocation, and the abdominal cavity was opened. The distal colon was harvested, opened longitudinally along the mesenteric border, stretched, and pinned flat on a Sylgard-coated petri dish (Sylgard 184, Dow Corning, Midland, MI). Tissues were fixed by immersion with 4% paraformaldehyde and 14% saturated picric acid in 0.1 M phosphate buffer (pH 7.4) for 4–6 h at 4°C. Thereafter, tissues were washed several times with 0.01 M PBS (pH 7.4) and maintained in PBS at 4°C. The mucosa, submucosa, and circular muscle layers were carefully removed, yielding a whole mount preparation consisting of the serosa and longitudinal muscle layer with the myenteric plexus attached to its internal side.

Fos Immunohistochemistry

Free-floating LMMP preparations of the mouse distal colon were incubated overnight at 4°C with rabbit polyclonal anti-Fos antibody in 0.01 M PBS (pH 7.4) containing 0.3% Triton X-100 (1:10,000; Oncogene, Cambridge, MA) as a primary antibody. Sections were then incubated with biotinylated secondary goat anti-rabbit IgG (1:1,000; Jackson ImmunoResearch) followed by an incubation with the avidin-biotin-peroxidase complex (1:400; Vector, Burlingame, CA), each lasting 1 h at room temperature. The chromogen was 3,3'-diaminobenzidine tetrachloride (DAB; 0.025%) with hydrogen peroxide (0.01%). After being stained, sections were mounted, air dried, dehydrated in ethanol, cleared in xylenes, and coverslipped. The presence of Fos immunoreactivity (IR) was revealed as a dark brown precipitate located in neuronal nuclei.

Double Staining of Fos and pChAT

LMMP preparations of the distal colon were stained for Fos IR as described above except that the secondary antibody was a Fab fragment (1:1,000; Jackson ImmunoResearch) and DAB staining was enhanced with nickel ammonia sulfate. Free-floating LMMP preparations were incubated with a specific pChAT antibody (Dr. H. Kimura) at 1:20,000 dilution in 0.1 M PBS containing 0.3% Triton X-100 for 48 h at 4°C, as previously reported (43, 65). Other procedures were the same as those described above for Fos immunohistochemistry except that the chromogen was DAB without color enhancement. With two cycles of immunostaining, Fos IR was detected as a dark blue nuclear reaction product, and pChAT-like IR (pChAT IR) appeared as brown staining in the cytoplasm.

For specificity of the primary antibody, preabsorption with specific antigens was performed. Ten micrograms of Fos (Oncogen) or 5 µg of pChAT peptide were added to the corresponding antibody solutions diluted at the working titer (1:10,000 and 1:20,000, respectively) and incubated for 24 h at 4°C. The preabsorbed solutions were then applied to colonic LMMP preparations as the primary antibody incubation. The other immunohistochemical procedures were the same.

Double Staining of Fos and NADPH-Diaphorase

Distal colon LMMP preparations were incubated at 37°C for 40 min in a freshly prepared solution containing -NADPH (0.5 mg/ml; Sigma) and nitroblue tetrazolium (0.1 mg/ml; Sigma) in 0.3% Triton X-100 in 0.1 M phosphate buffer (pH 7.4). After being thoroughly rinsed, tissue preparations were processed for Fos immunohistochemistry as described above. The presence of NADPH-diaphorase activity was detected as a diffused blue staining in the cytoplasm, whereas Fos IR appeared as a dark brown nuclear reaction product.

Cell Counting

Numbers of immunohistochemical-positive cells were counted under light microscopy in 20 ganglia randomly selected in 3–4 separate regions of each distal colonic LMMP preparation. Cell counting is expressed as the mean number of Fos-positive cells per ganglia in each mouse. For the double staining of Fos IR plus pChAT IR and Fos IR plus NADPH diaphorase, data are expressed as percentages of Fos IR plus pChAT IR or Fos- plus NADPH-diaphorase-positive cells from total Fos-positive cells and from total pChAT- or NADPH-diaphorase-positive cells, respectively.

Experimental Protocols

Effects of 5-HTP alone or with 5-HT₄ antagonist on defecation and fecal fluid content. 5-HTP (0.5, 1, 5, or 10 mg/kg), r/hCRF (20 µg/kg), or vehicle (0.1 ml/mouse) was administered intraperitoneally, and fecal pellet output and fecal fluid content were determined at 15-min intervals for the following 90 min. In a separate experiment, mice were injected intraperitoneally with the selective 5-HT₄ antagonist RS-39604 (1 or 3 mg/kg) or vehicle (0.1 ml) and 10 min later with 5-HTP (0.5 or 10 mg/kg) or vehicle (0.1 ml). Fecal pellet output and fecal fluid content were determined for the following 90 min. In each daily experiment, vehicle controls and different doses of the test substances were included and repeated on multiple days in different animals in a randomized fashion. Doses of 5-HTP, RS-39604, and CRF were based on preliminary data and previous reports (2, 33, 47).

Effects of 5-HTP on Fos expression in the mouse distal colonic myenteric plexus. In naïve mice, 5-HTP (0.5, 1, 5, or 10 mg/kg) or vehicle (0.1 ml) was administered intraperitoneally, and fecal pellet output and fecal fluid content were determined at 15-min intervals for the following 30 min. Separate groups of naïve mice were injected intraperitoneally with RS-39604 (3 mg/kg) or vehicle (0.1 ml) and 10 min later with 5-HTP (10 mg/kg) or vehicle (0.1 ml). Fecal pellet output was then determined for the following 30 min. In all cases, 90 min after 5-HTP or vehicle administration, mice were euthanized, and samples from the distal colon were collected for immunohistochemical staining of Fos and pChAT and histochemical staining of NADPH-diaphorase.

Statistical Analysis

Results are expressed as means ± SE. Comparisons within multiple groups were performed using one-way ANOVA followed by a Student-Newman-Keuls multiple-comparison test whenever appropriate. Comparisons between two groups were performed using a Student's t-test. The correlation between Fos expression and fecal pellet output was determined using linear regression. P values of <0.05 were considered statistically significant.

RESULTS

Stimulatory Effects of 5-HTP and r/hCRF Injected Intraperitoneally on Fecal Pellet Output and Fecal Fluid Content

In conscious mice, 5-HTP injected at 0.5, 1, and 5 mg/kg dose dependently increased fecal pellet output, with a plateau response at 5 and 10 mg/kg (Fig. 1 and Table 1). A time-course study showed a rapid onset with a peak increase of fecal pellet output and water content reached within 15 min postinjection. Thereafter, defecation scores returned to basal levels for theremaining 75-min period (Fig. 1 and Table 1). Although most of the fecal output was in the form of defined pellets, soft stools could be seen at all doses of 5-HTP. At 5 and 10 mg/kg, 5-HTP also induced diarrhea-like pellets (2–3 pellets of the total pellets from each mouse).

View larger version (13K): [in this window] [in a new window]   Fig. 1. Stimulation of fecal pellet output by 5-hydroxytryptophan (5-HTP) injected intraperitoneally in conscious mice: a time-course study. 5-HTP (0.5, 1, 5, or 10 mg/kg) or vehicle (0.1 ml) was injected intraperitoneally, and fecal pellet output was monitored at 15-min intervals for the following 90 min. The peak response was observed during the 15 min after 5-HTP administration. Thereafter, values were similar to those in vehicle-treated animals. Each point represents the mean ± SE of n = 5–6 mice/group. *P < 0.05 vs. other groups (by ANOVA).

Based on the time course of 5-HTP-induced defecation, fecal pellet output and fluid content were determined only during the first 30-min period after 5-HTP in all subsequent experiments.

RS-39604 Blocks Intraperitoneal 5-HTP-Induced Increases in Fecal Output and Fluid Content

In vehicle + vehicle-treated mice, pellet output during the 30-min experimental time was 2.4 ± 0.8 pellets/30 min (n = 7). RS-39604 injected intraperitoneally at either 1 or 3 mg/kg followed by intraperitoneal vehicle (n = 4 and 5, respectively) showed a similar tendency to reduce fecal pellet output, although statistical significance was not reached. Therefore, the two doses were pooled as a single group, with a 30-min cumulative pellet output of 0.7 ± 0.3 pellets/30 min (P > 0.05 vs. vehicle + vehicle; Fig. 2A). Pretreatment with RS-39604 at 1 mg/kg completely prevented the stimulatory effects of 5-HTP at 0.5 mg/kg (RS-39604 + 5-HTP: 1.4 ± 0.6 pellets/30 min, n = 5; vehicle + 5-HTP: 5.8 ± 0.9 pellets/30 min, n = 6; P < 0.05) while having only a partial antagonist action when 5-HTP was injected at 10 mg/kg (RS-39604 + 5-HTP: 5.3 ± 0.8 pellets/30 min, n = 9; vehicle + 5-HTP: 8.4 ± 1.2 pellets/30 min, n = 7; P < 0.05). RS-39604 at 3 mg/kg completely prevented the stimulatory effects of 5-HTP at 10 mg/kg (RS-39604 + 5-HTP: 1.6 ± 0.4 pellets/30 min, n = 5, P < 0.001 vs. vehicle + 5-HTP; Fig. 2A).

View larger version (16K): [in this window] [in a new window]   Fig. 2. Blockade of 5-HTP-induced defecation by the 5-HT4 antagonist RS-39604 in conscious mice. RS-39604 (1 or 3 mg/kg ip) or vehicle (0.1 ml ip) was injected immediately before 5-HTP (0.5 or 10 mg/kg ip) or vehicle (0.1 ml ip), and fecal pellet output (A), fecal wet weight (B), and fecal water fluid content (C) were determined 30 min later. Data corresponding to the RS-39604 + vehicle group represent a pooled group for the two doses of RS-39604 tested. Each column represents the mean ± SE of n = 5–9 mice/group. *P < 0.05 vs. vehicle + vehicle; #P < 0.05 vs. the respective 5-HTP + vehicle group (by ANOVA).

5-HTP Induces Fos Expression in Distal Colonic Myenteric Ganglia

In colonic LMMP preparations, myenteric ganglia were recognized as clearly delineated groups of neurons separated by well-defined internodal connections. The presence of Fos IR was restricted to cells located within the myenteric ganglia, and no Fos IR was observed in smooth muscle cells. LMMP preparations processed with the primary antibody preabsorbed with an excess of Fos protein did not show any Fos IR.

In mice injected intraperitoneally with vehicle, only a few scattered Fos-positive cells were observed in distal colonic myenteric ganglia (2.3 ± 0.6 cells/ganglion, n = 9). 5-HTP (0.5, 1, 5, or 10 mg/kg, n = 3–7 for each dose) dose dependently increased Fos expression by two-, two-, four-, and fivefold, respectively, over control values (Fig. 3). In the same animals, 5-HTP at 5 and 10 mg/kg also stimulated fecal pellet output to 13.7 ± 1.9 and 9.9 ± 1.0 pellets/30 min, respectively [both P < 0.05 vs. vehicle (3.0 ± 0.8 pellets/30 min), F_(4,22) = 9.342, P < 0.001]. The peak defecatory response occurred during the first 15 min after 5-HTP administration. Regardless of the 5-HTP doses tested, there was a linear correlation (r = 0.62, P = 0.0028) between pellet output during the 30-min period and the mean numbers of Fos-positive cells observed in myenteric ganglia of the distal colon, as determined in the same animals (Fig. 4).

View larger version (31K): [in this window] [in a new window]   Fig. 3. Fos expression induced by intraperitoneal 5-HTP in the myenteric plexus of the distal colon in conscious mice. A and B: representative microphotographs showing ganglionic Fos-positive cells in a longitudinal muscle/myenteric plexus (LMMP) preparation of the distal colon from animals treated with vehicle (A) or 5-HTP at 10 mg/kg (B). C: dose-related effects of 5-HTP (0.5–10 mg/kg) on Fos expression. Data are means ± SE from 3–9 animals/group. *P < 0.05 vs. vehicle (by ANOVA).

View larger version (12K): [in this window] [in a new window]   Fig. 4. Correlation between fecal pellet output and Fos expression in the colonic myenteric plexus. In animals treated with intraperitoneal vehicle or 5-HTP (0.5, 1, 5, or 10 mg/kg), fecal pellet output (numbers in 30 min) and Fos expression in colonic myenteric ganglia (Fos-positive cells/ganglion, means from 20 ganglia) were determined simultaneously. The plot shows the values for fecal pellet output and Fos-positive cells for each individual animal and the linear correlation.

Fos expression in myenteric ganglia in mice treated with vehicle + vehicle was low (2.7 ± 0.5 cells/ganglion, n = 4; Fig. 5). In vehicle-pretreated animals, 5-HTP (10 mg/kg ip) increased the numbers of Fos-positive cells in myenteric ganglia of the distal colon and fecal pellet output by 4.8- and 4.4-fold, respectively (Fig. 5). In accordance with previous experiments, the maximal pellet output response was observed during the 15-min period after 5-HTP administration. Pretreatment with RS-39604 prevented both the increase in Fos expression and stimulation of fecal pellet output induced by 5-HTP administration (Fig. 5, A and B). RS-39604, by itself, did not significantly modify Fos expression in distal colonic myenteric ganglia (Fig. 5A).

View larger version (66K): [in this window] [in a new window]   Fig. 5. Blockade of 5-HTP-induced fecal pellet output and Fos expression in the myenteric plexus of the distal colon by the selective 5-HT4 antagonist RS-39604. A: effects of RS-39604 (3 mg/kg ip) on 5-HTP (10 mg/kg ip)-induced Fos expression in the colonic myenteric plexus. Data are means ± SE of 4–5 animals/group and represent means of Fos-positive cells/ganglion. *P < 0.05 vs. other groups (by ANOVA). B: effects of RS-39604 (3 mg/kg ip) on 5-HTP (10 mg/kg ip)-induced fecal pellet output. Data are means ± SEM and represent pellet output during the first 30-min period after 5-HTP administration in the same animals included in A. *P < 0.05 vs. all other experimental groups (by ANOVA). C–F: representative microphotographs showing ganglionic Fos-positive cells in LMMP preparations of the distal colon from an animal treated with vehicle + vehicle (C), vehicle + 5-HTP (D), RS-39604 + vehicle (E), or RS-39604 + 5-HTP (F). Scale bar = 100 µm.

pChAT IR was found in numerous ganglion cells and was abundantly distributed in myenteric nerve fibers both within and between ganglia of the mouse distal colon (Fig. 6A). No pChAT-positive cell bodies were localized outside ganglionic structures, whereas pChAT-positive fibers could be observed running in the longitudinal colonic smooth muscle.

View larger version (121K): [in this window] [in a new window]   Fig. 6. Representative microphotographs of LMMP preparations from the distal colon of mice injected intraperitoneally with vehicle (A and C) and 5-HTP at 10 mg/kg (B and D) showing double labeling of Fos and peripheral choline acetyltransferase (pChAT; A and B) and Fos and NADPH-diaphorase (C and D). Arrows indicate double-labeled cells. Scale bar = 100 µm.

pChAT IR was completely absent in LMMP preparations incubated with pChAT antibody preabsorbed with an excess of blocking peptide.

5-HTP Induces Fos in a Population of NADPH-Diaphorase Neurons in Mouse Distal Colonic LMMP Preparations

Abundant NADPH-diaphorase-positive cells, predominantly with medium-sized cell bodies, were observed in myenteric ganglia of mouse distal colon LMMP preparations. Similarly, abundant NADPH-diaphorase-stained fibers were found in the internodal bundles (Fig. 6C). After the 5-HTP (10 mg/kg ip) injection, 21 ± 5% of ganglionic cells with Fos IR also had NADPH-diaphorase activity that encompassed 35 ± 5% of the NADPH-diaphorase-positive cells being double labeled with Fos IR (Fig. 6D).

DISCUSSION

The present study demonstrates that 5-HTP injected intraperitoneally in conscious mice increases Fos expression in colonic myenteric ganglia, as detected by immunohistochemistry in LMMP preparations of the distal colon, indicative of enteric neuronal activation (36, 37). The few Fos-positive cells detected in myenteric neurons after intraperitoneal vehicle and the dose-related increase in Fos expression induced by intraperitoneal 5-HTP show the specificity of the 5-HT precursor action. Monitoring Fos expression has been used previously to gain insight into changes in colonic myenteric activity after various treatments. However, all previous studies were restricted to rat or guinea pig colonic LMMP preparations (36, 37, 60, 67). The present study shows that Fos expression can be monitored in distal colonic myenteric neurons of mice, allowing the combined characterization of colonic myenteric neuronal activity and functional changes.

Convergent neuroanatomical and pharmacological evidence supports that intraperitoneal 5-HTP-induced Fos expression is mediated through 5-HT action on colonic 5-HT₄ receptors. First, 5-HT can be synthesized from 5-HTP within the gut wall, including colonic myenteric cell bodies and fibers as well as within EC and mast cells (64). Second, transcripts encoding the 5-HT_4a and 5-HT_4b splice variants of the 5-HT₄ receptor are abundantly expressed in the mouse colon (9, 32). Immunohistochemistry also revealed dense 5-HT₄ receptor labeling in mouse colonic myenteric ganglia (32, 48). Finally, pretreatment with RS-39604, a potent and selective 5-HT₄ antagonist that displays a 1,000-fold selectivity on 5-HT₄ over 5-HT_1A, 5-HT_2C, and 5-HT₃ receptors (23), completely prevented the occurrence of Fos expression in distal colonic myenteric neurons in response to an intraperitoneal injection of 5-HTP. In previous studies, the 5-HT₄-mediated excitatory action of 5-HT on myenteric neurons was investigated mainly in vitro in guinea pig ileum LMMP preparations (31, 46). More recently, a report (32) using cultured colonic myenteric neurons of young mice indicated that 5-HT₄ receptor activation increases the amplitude of nicotinic-evoked postsynaptic currents, suggesting a presynaptic action that strengthens excitatory neurotransmission. In addition, 5-HT₄-containing neurons localized by immunohistochemistry in the mouse did not show either regional differences in the small intestine and colon (32) or species difference among rats, mice, and guinea pigs (48). This supports the evidence showing that mouse colonic LMMP preparation can be another model to study 5-HT₄ receptor-mediated modulation of colonic motor function.

The biochemical coding of 5-HTP-activated neurons in the distal colonic LMMP preparation was investigated in relation to well-established cholinergic excitatory and NO inhibitory myenteric neurotransmitters involved in the regulation of the colonic peristaltic reflex in the mouse (21). The pChAT antiserum used in the present study was previously characterized by Western blot to be selective for the peripheral variant of ChAT, which is primarily expressed in enteric neurons (43, 61, 65). In a whole mount preparation cultured with colchicine, ChAT-positive myenteric neurons were detected in the mouse colon, although under these conditions, neuronal terminals were weakly stained (53). In the present study, the use of pChAT not only displayed more abundant neuronal cell bodies and fibers in the mouse distal colon than ChAT labeling but also enabled us to visualize cholinergic neurons in noncolchicine-treated LMMP preparations obtained after monitoring defecation in vivo and to correlate double labeling with Fos to functional changes and neuronal myenteric activity. We found that, after the 5-HTP injection, 40% of Fos-positive neurons were double labeled with pChAT and that Fos expression was prevented by a selective 5-HT₄ antagonist, showing 5-HT₄ receptor-mediated activation of a population of cholinergic myenteric neurons. Most of the cholinergic cells in the myenteric plexus of the mouse distal colon displayed features of Dogiel type I neurons (53), which include motor neurons and interneurons (44). The colocalization of Fos IR and pChAT IR occurred mostly in this group of neurons. Although not further characterized, activated neurons are likely to encompass cholinergic myenteric motor neurons that are involved in the contractile response of the ascending component of the peristaltic reflex (21). Interestingly, 5-HT₄ receptors have recently been identified on Dogiel type II neurons of mouse colonic myenteric ganglia, which correspond to intrinsic primary afferent neurons whose activation triggers motility and secretory reflexes (48). Although we could identify, with relative frequency, pChAT-positive, Dogiel type II-like neurons in LMMP preparations, these neurons were mostly Fos negative, suggesting that most of them were not activated.

In the rat enteric nervous system, none of the pChAT-positive neurons were found double stained with NADPH-diaphorase (43), suggesting that the non-pChAT neurons activated by intraperitoneal 5-HTP in the colon may encompass, at least in part, a distinct population of NO-synthesizing neurons. Indeed, we demonstrated that 21% of the 5-HTP-activated cells in myenteric ganglia of the distal colon were also NADPH-diaphorase positive. The ascending and descending components of the peristaltic reflex encompass excitatory (cholinergic/tachykinergic) and inhibitory (VIP/PACAP/NO) motor neurons that act orally and caudally, respectively, to coordinate propulsive motor responses in the mouse colon (21). We found that the 5-HT₄ antagonist completely prevented Fos expression in myenteric neurons, which include both pChAT- and NADPH-positive cells. In addition, there was a correlation between the Fos expression in distal colonic myenteric neurons and colonic propulsive motor function elicited by 5-HTP. Distention in isolated intestinal segments from the guinea pig has been reported to induce Fos expression in myenteric neurons (50), suggesting a possible role of mechanical events in the Fos response. However, it is unlikely that Fos expression in distal colonic myenteric neurons is secondary to increased colonic motility induced by intraperitoneal 5-HTP. First, 180 min of intestinal distention was required to induce the Fos response, whereas in our experiments, colonic propulsive motility was increased only for the first 15 min. In addition, in our previous studies, Fos expression occurring in response to central vagal activation in gastric or colonic myenteric neurons induced by intraperitoneal CRF was not modified by atropine at doses that blocked the increased motility (36, 38, 66). In addition to direct peripheral effects on the myenteric nervous system, whether 5-HTP, known to increase 5-HT in the central nervous system, could also influence Fos expression through central pathways needs to be investigated. However, kinetics of 5-HT occurrence in the brain after 5-HTP administration is more delayed compared with the viscera, and the doses at which central nervous system actions of 5-HTP have been reported are about 10-fold higher than those in the periphery (62). Taken together, these data provide strong support, in an in vivo model, of previous in vitro data pointing to the peripheral activation of 5-HT₄ receptors being responsible for the initiation of the peristaltic reflex in the mouse distal colon (21).

In addition to enteric neurons, colonic smooth muscles, unlike epithelial cells, are also endowed with 5-HT₄ receptors, as detected both at gene and protein levels in mice (32, 48). However, activation of 5-HT₄ receptors located on smooth muscle cells results largely in an inhibitory response, as shown by the TTX-independent relaxation of isolated canine and human rectal circular smooth muscle and rat ileum longitudinal segments induced by selective 5-HT₄ agonists and the selective blockade of these responses by 5-HT₄ antagonists (30, 49, 54, 59). It cannot be ruled out that the recruitment of these inhibitory mechanisms occurring directly on smooth muscle cells may counteract the stimulatory response and plays a role in the short-lasting action of 5-HTP and the trend to have a maximum colonic motor effect (pellet output and weight) at 5 mg/kg and a lesser effect at 10 mg/kg.

In addition to its motor effects, 5-HTP injected intraperitoneally increased fecal fluid content, and, for the higher doses tested, diarrheic responses could be seen within 15–30 min. These data are consistent with previous observations in mice injected with 5-HTP subcutaneously or intraperitoneally (2, 42, 47). This probably reflects specific 5-HTP-mediated effects on colonic secretion of fluid and electrolytes rather than an increased passage of fecal content. 5-HT evokes fluid diarrhea through the stimulation of chloride and mucus secretion from the intestinal mucosa (7). Morphological studies have shown the presence of 5-HT₄ receptors in colonic submucosal ganglia, although they were almost entirely absent from secretomotor neurons (48). Of note, the pattern of defecation and increased fecal water content induced by 5-HTP was similar to that observed by intraperitoneal CRF, reported to accelerate distal colonic transit in mice (33) and to act through the activation of myenteric neuronal mechanisms in the rat colon (36, 57). The actions of 5-HTP are 5-HT₄ receptor mediated, as shown by the complete blockade of the 5-HTP-induced increase in fecal output and fluid content by RS-39604. Previous reports have shown that the 5-HT₄ antagonist SB-207266, injected subcutaneoulsy, prevented the subcutaneous 5-HTP-evoked increase in pellet output and fecal fluid content in conscious mice (2, 54, 56). Interestingly, the 5-HT₄ antagonist by itself had a tendency to reduce pellet output and significantly reduced fecal fluid content compared with vehicle-treated mice. This suggests that 5-HT₄ receptors are involved in the basal regulation of colonic motility and secretion, supporting recent functional observations in knockout mice lacking 5-HT₄ receptors (19). These animals have an abnormally slow colorectal motility, with normal gastric emptying or small intestine motility, thus suggesting that 5-HT₄ receptors are necessary to maintain a normal colonic motility (19). Similarly, in isolated longitudinal muscle strips of the rat distal colon, 5-HT₄ receptors have been recently reported to participate in the regulation of spontaneous contractions (45). These data, however, contrast with previous reports suggesting that 5-HT₄ receptors play little or no role in regulating basal colonic motility and their functional implication mainly lies in response to 5-HT-induced altered gut function (2, 42, 54, 56).

In summary, the present study established the use of Fos combined with pChAT and NADPH-diaphorase histochemistry in LMMP preparations of the mouse distal colon to detect activation of myenteric cholinergic and nitrergic neurons in conscious mice. We demonstrated that the 5-HT precursor 5-HTP, injected intraperitoneally, induces a 5-HT₄ receptor-mediated dose-related activation of distal colonic myenteric neurons, which correlated with the stimulation of colonic motor function. Fos expression in the distal colon encompasses separate populations of pChAT- and NADPH-diaphorase-positive neurons, known to be involved in the peristaltic reflex in mice (21). These observations support a role for 5-HT, acting through 5-HT₄ receptors in myenteric neurons in the control of colonic motility, and suggest that these mechanisms might be implicated in the pathophysiology of IBS and/or other colonic disorders characterized by altered motility and defecation.

GRANTS

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants RO1-DK-57238, DK-41301 (Animal Core), and P50-DK-64539 and by a Veterans Affairs Career Scientist Award.

ACKNOWLEDGMENTS

We thank Dr. Jean Rivier (Salk Institute, La Jolla, CA) for the generous donation of r/hCRF and Teresa Olivas for editing the manuscript.

FOOTNOTES

Address for reprint requests and other correspondence: L. Wang, Bldg. 115, Rm. 117B, 11301 Wilshire Blvd., Los Angeles, CA 90073 (e-mail: lixinw{at}ucla.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

REFERENCES

1. Appel S, Kumle A, Hubert M, Duvauchelle T. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine₄ receptor agonist. J Clin Pharmacol 37: 229–237, 1997.[Abstract]
2. Banner SE, Smith MI, Bywater D, Gaster LM, Sanger GJ. Increased defaecation caused by 5-HT₄ receptor activation in the mouse. Eur J Pharmacol 308: 181–186, 1996.[CrossRef][Web of Science][Medline]
3. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 42: 42–46, 1998.[Abstract/Free Full Text]
4. Benditt EP, Wong GRL. On the concentration of 5-hydroxytryptamine in mammalian enterochromaffin cells and its release by reserpine. J Exp Med 105: 509–520, 1957.[Abstract/Free Full Text]
5. Bjornsson ES, Chey WD, Ladabaum U, Woods ML, Hooper FG, Owyang C, Hasler WL. Differential 5-HT₃ mediation of human gastrocolonic response and colonic peristaltic reflex. Am J Physiol Gastrointest Liver Physiol 275: G498–G505, 1998.[Abstract/Free Full Text]
6. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT₄ agonist, prucalopride, in healthy humans. Gut 44: 682–686, 1999.[Abstract/Free Full Text]
7. Budhoo MR, Kellum JM. Evidence for a 5-HT₄ receptor pathway mediating chloride secretion in the rat distal colon. J Surg Res 57: 44–48, 1994.[CrossRef][Web of Science][Medline]
8. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123: 425–432, 2002.[CrossRef][Web of Science][Medline]
9. Claeysen S, Sebben M, Becamel C, Bockaert J, Dumuis A. Novel brain-specific 5-HT₄ receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 55: 910–920, 1999.[Abstract/Free Full Text]
10. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657–1664, 2004.[CrossRef][Web of Science][Medline]
11. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 141: 1285–1293, 2004.[CrossRef][Web of Science][Medline]
12. Curran T, Morgan JI. Fos: an immediate-early transcription factor in neurons. J Neurobiol 26: 403–412, 1995.[CrossRef][Web of Science][Medline]
13. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3: 349–357, 2005.[CrossRef][Web of Science][Medline]
14. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125: 1651–1659, 2003.[CrossRef][Web of Science][Medline]
15. Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 111: 1281–1290, 1996.[CrossRef][Web of Science][Medline]
16. Fujimiya M, Okumiya K, Yamane T, Maeda T. Distribution of serotonin-immunoreactive nerve cells and fibers in the rat gastrointestinal tract. Histochem Cell Biol 107: 105–114, 1997.[CrossRef][Web of Science][Medline]
17. Furness JB, Robbins HL, Xiao J, Stebbing MJ, Nurgali K. Projections and chemistry of Dogiel type II neurons in the mouse colon. Cell Tissue Res 317: 1–12, 2004.[Web of Science][Medline]
18. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13, Suppl 2: 15–30, 1999.
19. Gershon MD. Review article: serotonin receptors and transporters–roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20, Suppl 7: 3–14, 2004.
20. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 4: 139–144, 1990.[Web of Science][Medline]
21. Grider JR. Neurotransmitters mediating the intestinal peristaltic reflex in the mouse. J Pharmacol Exp Ther 307: 460–467, 2003.[Abstract/Free Full Text]
22. Hedge SS, Moy TM, Perry MR, Loeb M, Eglen RM. Evidence for the involvement of 5-hydroxytryptamine 4 receptors in 5-hydroxytryptophan-induced diarrhea in mice. J Pharmacol Exp Ther 271: 741–747, 1994.[Abstract/Free Full Text]
23. Hegde SS, Bonhaus DW, Johnson LG, Leung E, Clark RD, Eglen RM. RS 39604: a potent, selective and orally active 5-HT₄ receptor antagonist. Br J Pharmacol 115: 1087–1095, 1995.[Web of Science][Medline]
24. Hope BT, Vincent SR. Histochemical characterization of neuronal NADPH-diaphorase. J Histochem Cytochem 37: 653–661, 1989.[Abstract]
25. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT₃ receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 14: 775–782, 2000.[CrossRef][Web of Science][Medline]
26. Inui A, Yoshikawa T, Nagai R, Yoshida N, Ito T. Effects of mosapride citrate, a 5-HT₄ receptor agonist, on colonic motility in conscious guinea pigs. Jpn J Pharmacol 90: 313–320, 2002.[CrossRef][Medline]
27. Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT₄ and 5-HT₃ receptors. J Pharmacol Exp Ther 288: 93–97, 1999.[Abstract/Free Full Text]
28. Kadowaki M, Wade PR, Gershon MD. Participation of 5-HT₃, 5-HT₄, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. Am J Physiol Gastrointest Liver Physiol 271: G849–G857, 1996.[Abstract/Free Full Text]
29. Kadowaki M, Wang XO, Shimatani H, Yoneda S, Takaki M. 5-HT₄ receptor enhances the propulsive power of the peristaltic reflex in the rat distal colon. Auton Neurosci 99: 62–65, 2002.[CrossRef][Web of Science][Medline]
30. Leclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5-HT₄ receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 17: 366–375, 2005.[CrossRef][Web of Science][Medline]
31. LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum. Neurogastroenterol Motil 16: 355–364, 2004.[CrossRef][Web of Science][Medline]
32. Liu M, Geddis MS, Wen Y, Setlik W, Gershon MD. Expression and function of 5-HT₄ receptors in the mouse enteric nervous system. Am J Physiol Gastrointest Liver Physiol 289: G1148–G1163, 2005.[Abstract/Free Full Text]
33. Martinez V, Wang L, Rivier JE, Vale W, Taché Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 301: 611–617, 2002.[Abstract/Free Full Text]
34. Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 23: 1067–1076, 2006.[CrossRef][Web of Science][Medline]
35. Mazzia C, Hicks GA, Clerc N. Neuronal location of 5-hydroxytryptamine₃ receptor-like immunoreactivity in the rat colon. Neuroscience 116: 1033–1041, 2003.[CrossRef][Web of Science][Medline]
36. Miampamba M, Maillot C, Million M, Taché Y. Peripheral CRF activates myenteric neurons in the proximal colon through CRF₁ receptor in conscious rats. Am J Physiol Gastrointest Liver Physiol 282: G857–G865, 2002.[Abstract/Free Full Text]
37. Miampamba M, Sharkey KA. c-Fos expression in the myenteric plexus, spinal cord and brainstem following injection of formalin in the rat colonic wall. J Auton Nerv Syst 77: 140–151, 1999.[CrossRef][Web of Science][Medline]
38. Miampamba M, Yang H, Sharkey KA, Taché Y. Intracisternal TRH analog induces Fos expression in gastric myenteric neurons and glia in conscious rats. Am J Physiol Gastrointest Liver Physiol 280: G979–G991, 2001.[Abstract/Free Full Text]
39. Michel K, Zeller F, Langer R, Nekarda H, Kruger D, Dover TJ, Brady CA, Barnes NM, Schemann M. Serotonin excites neurons in the human submucous plexus via 5-HT₃ receptors. Gastroenterology 128: 1317–1326, 2005.[CrossRef][Web of Science][Medline]
40. Miyata K, Ito H, Fukudo S. Involvement of the 5-HT₃ receptor in CRH-induce defecation in rats. Am J Physiol Gastrointest Liver Physiol 274: G827–G831, 1998.[Abstract/Free Full Text]
41. Nagakura Y, Ito H, Kiso T, Naitoh Y, Miyata K. The selective 5-hydroxytryptamine (5-HT)₄-receptor agonist RS67506 enhances lower intestinal propulsion in mice. Jpn J Pharmacol 74: 209–212, 1997.[Medline]
42. Nagakura Y, Kontoh A, Tokita K, Tomoi M, Shimomura K, Kadowaki M. Combined blockade of 5-HT₃- and 5-HT₄-serotonin receptors inhibits colonic functions in conscious rats and mice. J Pharmacol Exp Ther 281: 284–290, 1997.[Abstract/Free Full Text]
43. Nakajima K, Tooyama I, Yasuhara O, Aimi Y, Kimura H. Immunohistochemical demonstration of choline acetyltransferase of a peripheral type (pChAT) in the enteric nervous system of rats. J Chem Neuroanat 18: 31–40, 2000.[CrossRef][Web of Science][Medline]
44. Nurgali K, Stebbing MJ, Furness JB. Correlation of electrophysiological and morphological characteristics of enteric neurons in the mouse colon. J Comp Neurol 468: 112–124, 2004.[CrossRef][Web of Science][Medline]
45. Ono S, Mitsui R, Karaki S, Kuwahara A. Muscarinic and 5-HT₄ receptors participate in the regulation of the frequency of spontaneous contractions of the longitudinal muscle in rat distal colon. Biomed Res (Tokyo) 26: 173–177, 2005.
46. Pan H, Galligan JJ. 5-HT_1A and 5-HT₄ receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons. Am J Physiol Gastrointest Liver Physiol 266: G230–G238, 1994.[Abstract/Free Full Text]
47. Pascual D, Alsasua A, Goicoechea C, Martin MI. The involvement of 5-HT₃ and 5-HT₄ receptors in two models of gastrointestinal transit in mice. Neurosci Lett 326: 163–166, 2002.[CrossRef][Web of Science][Medline]
48. Poole DP, Xu B, Koh SL, Hunne B, Coupar IM, Irving HR, Shinjo K, Furness JB. Identification of neurons that express 5-hydroxytryptamine₄ receptors in intestine. Cell Tissue Res 325: 413–422, 2006.[CrossRef][Web of Science][Medline]
49. Prins NH, Shankley NP, Welsh NJ, Briejer MR, Lefebvre RA, Akkermans LM, Schuurkes JA. An improved in vitro bioassay for the study of 5-HT₄ receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 129: 1601–1608, 2000.[CrossRef][Web of Science][Medline]
50. Ritter RC, Costa M, Brookes SH. Nuclear Fos immunoreactivity in guinea pig myenteric neurons following activation of motor activity. Am J Physiol Gastrointest Liver Physiol 273: G498–G507, 1997.[Abstract/Free Full Text]
51. Sakurai-Yamashita Y, Yamashita K, Kanematsu T, Taniyama K. Localization of the 5-HT₄ receptor in the human and the guinea pig colon. Eur J Pharmacol 383: 281–285, 1999.[CrossRef][Web of Science][Medline]
52. Sang Q, Williamson S, Young HM. Projections of chemically identified myenteric neurons of the small and large intestine of the mouse. J Anat 190: 209–222, 1997.
53. Sang Q, Young HM. The identification and chemical coding of cholinergic neurons in the small and large intestine of the mouse. Anat Rec 251: 185–199, 1998.[CrossRef][Medline]
54. Sanger GJ, Banner SE, Smith MI, Wardle KA. SB-207266: 5-HT₄ receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models. Neurogastroenterol Motil 10: 271–279, 1998.[CrossRef][Web of Science][Medline]
55. Sanger GJ, McClelland CM. Increased gastric cholinergic activity evoked by 5-hydroxy-L-tryptophan in the rat. Eur J Pharmacol 127: 179–185, 1986.[CrossRef][Web of Science][Medline]
56. Sanger GJ, Yoshida M, Yahyah M, Kitazumi K. Increased defecation during stress or after 5-hydroxytryptophan: selective inhibition by the 5-HT₄ receptor antagonist, SB-207266. Br J Pharmacol 130: 706–712, 2000.[CrossRef][Web of Science][Medline]
57. Saunders PR, Maillot C, Million M, Taché Y. Peripheral corticotropin-releasing factor induces diarrhea in rats: role of CRF₁ receptor in fecal watery excretion. Eur J Pharmacol 435: 231–235, 2002.[CrossRef][Web of Science][Medline]
58. Sonda S, Kawahara T, Katayama K, Sato N, Asano K. Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT₄ receptor agonists. Bioorg Med Chem 13: 3295–3308, 2005.[CrossRef][Medline]
59. Taniyama K, Makimoto N, Furuichi A, Sakurai-Yamashita Y, Nagase Y, Kaibara M, Kanematsu T. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine₄ receptor, in gastrointestinal motility. J Gastroenterol 35: 575–582, 2000.[CrossRef][Web of Science][Medline]
60. Tjwa ET, Bradley JM, Keenan CM, Kroese AB, Sharkey KA. Interleukin-1 activates specific populations of enteric neurons and enteric glia in the guinea pig ileum and colon. Am J Physiol Gastrointest Liver Physiol 285: G1268–G1276, 2003.[Abstract/Free Full Text]
61. Tooyama I, Kimura H. A protein encoded by an alternative splice variant of choline acetyltransferase mRNA is localized preferentially in peripheral nerve cells and fibers. J Chem Neuroanat 17: 217–226, 2000.[CrossRef][Web of Science][Medline]
62. Udenfriend S, Weissbach H, Bogdanksi DF. Increase in tissue serotonin following administration of its precursor 5-hydroxytryptophan. J Biol Chem 224: 803–810, 1957.[Free Full Text]
63. Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 17: 863–870, 2005.[CrossRef][Web of Science][Medline]
64. Yu PL, Fujimura M, Okumiya K, Kinoshita M, Hasegawa H, Fujimiya M. Immunohistochemical localization of tryptophan hydroxylase in the human and rat gastrointestinal tracts. J Comp Neurol 411: 654–665, 1999.[CrossRef][Web of Science][Medline]
65. Yuan PQ, Kimura H, Million M, Bellier JP, Wang L, Ohning GV, Taché Y. Central vagal stimulation activates enteric cholinergic neurons in the stomach and VIP neurons in the duodenum in conscious rats. Peptides 26: 653–664, 2005.[CrossRef][Web of Science][Medline]
66. Yuan PQ, Taché Y, Miampamba M, Yang H. Acute cold exposure induces vagally mediated Fos expression in gastric myenteric neurons in conscious rats. Am J Physiol Gastrointest Liver Physiol 281: G560–G568, 2001.[Abstract/Free Full Text]
67. Yuyama N, Mizuno J, Tsuzuki H, Wada-Takahashi S, Takahashi O, Tamura K. Effects of extrinsic autonomic inputs on expression of c-Fos immunoreactivity in myenteric neurons of the guinea pig distal colon. Brain Res 948: 8–16, 2002.[CrossRef][Web of Science][Medline]

This article has been cited by other articles:

				L. Wang, G. Gourcerol, P.-Q. Yuan, S. V. Wu, M. Million, M. Larauche, and Y. Tache Peripheral peptide YY inhibits propulsive colonic motor function through Y2 receptor in conscious mice Am J Physiol Gastrointest Liver Physiol, January 1, 2010; 298(1): G45 - G56. [Abstract] [Full Text] [PDF]

				R. Tanaka, A. Inui, A. Asakawa, K. Atsuchi, K. Ataka, and M. Fujimiya New method of manometric measurement of gastroduodenal motility in conscious mice: effects of ghrelin and Y2 depletion Am J Physiol Gastrointest Liver Physiol, November 1, 2009; 297(5): G1028 - G1034. [Abstract] [Full Text] [PDF]

				M. H. Mueller, B. Xue, J. Glatzle, J. Hahn, D. Grundy, and M. E. Kreis Extrinsic afferent nerve sensitivity and enteric neurotransmission in murine jejunum in vitro Am J Physiol Gastrointest Liver Physiol, October 1, 2009; 297(4): G655 - G662. [Abstract] [Full Text] [PDF]

				G. Gourcerol, L. Wang, D. W. Adelson, M. Larauche, Y. Tache, and M. Million Cholinergic giant migrating contractions in conscious mouse colon assessed by using a novel noninvasive solid-state manometry method: modulation by stressors Am J Physiol Gastrointest Liver Physiol, May 1, 2009; 296(5): G992 - G1002. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 292/1/G419    most recent 00289.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Wang, L. Articles by Taché, Y. Search for Related Content PubMed PubMed Citation Articles by Wang, L. Articles by Taché, Y.